MetaCap

Eton Pharmaceuticals (ETON) vs First Tracks Biotherapeutics (TRAX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Eton Pharmaceuticals is the larger company by market cap ($1.76 billion vs $1.75 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ETON+143.40%TRAX+119.16%
+185%+78%-29%
Apr 6, 20261 yearNov 20, 2026
ETON+130.84%TRAX+77.19%
+151%+55%-41%
Apr 6, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ETON versus TRAX key metrics
MetricETONTRAX
Share price$60.85$41.64
Market cap$1.76B$1.75B
1-day change-0.83%-6.34%
YTD return+259.85%—
1-year return+269.68%—
5-year return+1341.94%—
P/E ratio (TTM)39.51—
Forward P/E18.41—
EPS (TTM)$1.54$-4.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$79.95M—
Revenue growth (YoY)+104.94%—
Net income (latest FY)$-4.60M—
Gross margin53.46%—
Operating margin-1.06%—
Net margin-5.75%—
52-week high$70.64$54.78
52-week low$14.27$14.72
Distance from 52-week high-13.86%-23.99%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+32.70%+80.52%
Average volume570.79K826.70K
Shares outstanding28.84M42.02M
Employees44104
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Eton Pharmaceuticals

ETON stock →

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.

Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees

About First Tracks Biotherapeutics

TRAX stock →

First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 104 employees

ETON vs TRAX FAQ

Which is bigger, Eton Pharmaceuticals or First Tracks Biotherapeutics?

Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.76B compared with $1.75B for First Tracks Biotherapeutics (TRAX).

Are Eton Pharmaceuticals and First Tracks Biotherapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons